Literature DB >> 9860497

Chiral inversion and hydrolysis of thalidomide: mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites.

M Reist1, P A Carrupt, E Francotte, B Testa.   

Abstract

The chiral inversion and hydrolysis of thalidomide and the catalysis by bases and human serum albumin were investigated by using a stereoselective HPLC assay. Chiral inversion was catalyzed by albumin, hydroxyl ions, phosphate, and amino acids. Basic amino acids (Arg and Lys) had a superior potency in catalyzing chiral inversion compared to acid and neutral ones. The chiral inversion of thalidomide is thus subject to specific and general base catalysis, and it is suggested that the ability of HSA to catalyze the reaction is due to the basic groups of the amino acids Arg and Lys and not to a single catalytic site on the macromolecule. The hydrolysis of thalidomide was also base-catalyzed. However, albumin had no effect on hydrolysis, and there was no difference between the catalytic potencies of acidic, neutral, and basic amino acids. This may be explained by different reaction mechanisms of the chiral inversion and hydrolysis of thalidomide. Chiral inversion is deduced to occur by electrophilic substitution involving specific and general base catalysis, whereas hydrolysis is thought to occur by nucleophilic substitution involving specific and general base as well as nucleophilic catalysis. As nucleophilic attack is sensitive to steric properties of the catalyst, steric hindrance might be the reason albumin is not able to catalyze hydrolysis. 1H NMR experiments revealed that the three teratogenic metabolites of thalidomide, in sharp contrast to the drug itself, had complete chiral stability. This leads to the speculation that, were some enantioselectivity to exist in the teratogenicity of thalidomide, it could result from fast hydrolysis to chirally stable teratogenic metabolites.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9860497     DOI: 10.1021/tx9801817

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  17 in total

1.  Urban legends of chemistry.

Authors:  Michelle Francl
Journal:  Nat Chem       Date:  2010-08       Impact factor: 24.427

2.  Human cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analogue of thalidomide.

Authors:  Goutam Chowdhury; Norio Shibata; Hiroshi Yamazaki; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2013-12-24       Impact factor: 3.739

3.  Transport of thalidomide by the human intestinal caco-2 monolayers.

Authors:  Shufeng Zhou; Yan Li; Phillip Kestell; Peter Schafer; Eli Chan; James W Paxton
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Jan-Jun       Impact factor: 2.441

Review 4.  Thalidomide-type teratogenicity: structure-activity relationships for congeners.

Authors:  R L Smith; S C Mitchell
Journal:  Toxicol Res (Camb)       Date:  2018-09-26       Impact factor: 3.524

Review 5.  Thalidomide in cancer treatment: a potential role in the elderly?

Authors:  Shufeng Zhou; Philip Kestell; Malcolm D Tingle; James W Paxton
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

6.  Phenyl-Glutarimides: Alternative Cereblon Binders for the Design of PROTACs.

Authors:  Jaeki Min; Anand Mayasundari; Fatemeh Keramatnia; Barbara Jonchere; Seung Wook Yang; Jamie Jarusiewicz; Marisa Actis; Sourav Das; Brandon Young; Jake Slavish; Lei Yang; Yong Li; Xiang Fu; Shalandus H Garrett; Mi-Kyung Yun; Zhenmei Li; Stanley Nithianantham; Sergio Chai; Taosheng Chen; Anang Shelat; Richard E Lee; Gisele Nishiguchi; Stephen W White; Martine F Roussel; Patrick Ryan Potts; Marcus Fischer; Zoran Rankovic
Journal:  Angew Chem Int Ed Engl       Date:  2021-11-16       Impact factor: 15.336

7.  Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine and its enantiomers in mice: pharmacokinetic considerations.

Authors:  William E Fantegrossi; Naoki Murai; Brian O Mathúna; Nieves Pizarro; Rafael de la Torre
Journal:  J Pharmacol Exp Ther       Date:  2009-03-10       Impact factor: 4.030

8.  Defining Metabolic and Nonmetabolic Regulation of Histone Acetylation by NSAID Chemotypes.

Authors:  Jonathan H Shrimp; Julie M Garlick; Tugsan Tezil; Alexander W Sorum; Andrew J Worth; Ian A Blair; Eric Verdin; Nathaniel W Snyder; Jordan L Meier
Journal:  Mol Pharm       Date:  2017-12-29       Impact factor: 4.939

9.  Enantioselective synthesis of 3-arylquinazolin-4(3H)-ones via peptide-catalyzed atroposelective bromination.

Authors:  Matthew E Diener; Anthony J Metrano; Shuhei Kusano; Scott J Miller
Journal:  J Am Chem Soc       Date:  2015-09-18       Impact factor: 15.419

Review 10.  Clinical pharmacokinetics of thalidomide.

Authors:  Steve K Teo; Wayne A Colburn; William G Tracewell; Karin A Kook; David I Stirling; Markian S Jaworsky; Michael A Scheffler; Steve D Thomas; Oscar L Laskin
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 5.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.